Table 1.

Patient and tumor characteristics according to LATS2 mRNA expression (A) and LATS2 protein expression (B).

(A) LATS2 mRNA expression
	High LATS2 expression	Low LATS2 expression	P-value
N (%)	23 (46.9)	26 (53.1)
Follow-up duration (day), mean ± S.D.	1276 ± 404
Gender, n (%), M:F	23:26		0.907
Male	11 (22.4)	12 (24.5)
Female	12 (24.5)	14 (28.6)
Age, mean ± S.D.	64.1 ± 9.2		0.336
	66.3 ± 7.6	62.2 ± 10.2
Smoking, n (%), SM:NS	19:30		0.590
SM	8 (16.3)	11 (22.4)
NS	15 (30.6)	15 (30.6)
Stage, n (%), I:II:III	29:12:08		0.709
Stage I	15 (30.6)	14 (28.6)
Stage II	5 (10.2)	7 (14.3)
Stage III	3 (6.1)	5 (10.2)
In groups			0.706
Earlier stage (I and II)	20 (40.8)	21 (42.9)
Advanced stage (III)	3 (6.1)	5 (10.2)
Relapse, n (%)			0.015*
Yes	7 (14.3)	17 (34.7)
No	16 (32.7)	9 (18.4)
DFS (day), median	919
	1303	746	0.006*
Death, n (%)			0.044*
Yes	3 (6.1)	10 (20.4)
No	20 (40.8)	16 (32.7)
OS (day), median	1095
	1364	794	0.059
EGFR, n (%), Mut:WT	21:28		0.283
Mutation (Mut)	8 (16.3)	13 (26.5)
Wild type (WT)	15 (30.6)	13 (26.5)

(B) LATS2 IHC staining
	Above mean	Below mean	P-value
N (%)	32 (50.8)	31 (49.2)
Gender, n (%), M:F	36:27		0.021*
Male	18 (36)	18 (36)
Female	13 (26)	14 (28)
EGFR, n (%), Mut:WT	37:22		0.01*
Mutation (Mut)	18 (36)	19 (38)
Wild type (WT)	11 (22)	11 (22)

(C) EGFR mutation status of samples included in this study
		Samples for mRNA measurement	Samples for IHC
EGFR wild-type		28	22
	Exon 18	4	3
	Exon 19	8	10
	Exon 20	1	1
EGFR mutation	Exon 21	7	6
	L858R + T790M	1	1
	Unknown	0	27

^*Statistically significant (p < 0.05).